Omics sciences and precision medicine in colon cancer.

Q2 Medicine

Clinica Terapeutica Pub Date : 2023-11-01 DOI:10.7417/CT.2023.2472

G Madeo, G Bonetti, M Gadler, S Benedetti, G Guerri, F Cristofoli, D Generali, C A Donofrio, M Cominetti, A Fioravanti, L Riccio, A Bernini, E Fulcheri, A Iaconelli, B Aquilanti, G Matera, L Stuppia, V Gatta, S Cecchin, G Marceddu, M Bertelli

{"title":"Omics sciences and precision medicine in colon cancer.","authors":"G Madeo, G Bonetti, M Gadler, S Benedetti, G Guerri, F Cristofoli, D Generali, C A Donofrio, M Cominetti, A Fioravanti, L Riccio, A Bernini, E Fulcheri, A Iaconelli, B Aquilanti, G Matera, L Stuppia, V Gatta, S Cecchin, G Marceddu, M Bertelli","doi":"10.7417/CT.2023.2472","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Colon cancer presents a complex pathophysiological landscape, which poses a significant challenge to the precise prediction of patient prognosis and treatment response. However, the emergence of omics sciences such as genomics, transcriptomics, proteomics, and metabolomics has provided powerful tools to identify molecular alterations and pathways involved in colon cancer development and progression. To address the lack of literature exploring the intersection of omics sciences, precision medicine, and colon cancer, we conducted a comprehensive search in ScienceDirect and PubMed databases. We included systematic reviews, reviews, case studies, clinical studies, and randomized controlled trials that were published between 2015-2023. To refine our search, we excluded abstracts and non-English studies. This review provides a comprehensive summary of the current understanding of the latest developments in precision medicine and omics sciences in the context of colon cancer. Studies have identified molecular subtypes of colon cancer based on genomic and transcrip-tomic profiles, which have implications for prognosis and treatment selection. Furthermore, precision medicine (which involves tailoring treatments, based on the unique molecular characteristics of each patient's tumor) has shown promise in improving outcomes for colon cancer patients. Omics sciences and precision medicine hold great promise for identifying new therapeutic targets and developing more effective treatments for colon cancer. Although not strictly designed as a systematic review, this review provides a readily accessible and up-to-date summary of the latest developments in the field, highlighting the challenges and opportunities for future research.</p>","PeriodicalId":50686,"journal":{"name":"Clinica Terapeutica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Terapeutica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7417/CT.2023.2472","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: Colon cancer presents a complex pathophysiological landscape, which poses a significant challenge to the precise prediction of patient prognosis and treatment response. However, the emergence of omics sciences such as genomics, transcriptomics, proteomics, and metabolomics has provided powerful tools to identify molecular alterations and pathways involved in colon cancer development and progression. To address the lack of literature exploring the intersection of omics sciences, precision medicine, and colon cancer, we conducted a comprehensive search in ScienceDirect and PubMed databases. We included systematic reviews, reviews, case studies, clinical studies, and randomized controlled trials that were published between 2015-2023. To refine our search, we excluded abstracts and non-English studies. This review provides a comprehensive summary of the current understanding of the latest developments in precision medicine and omics sciences in the context of colon cancer. Studies have identified molecular subtypes of colon cancer based on genomic and transcrip-tomic profiles, which have implications for prognosis and treatment selection. Furthermore, precision medicine (which involves tailoring treatments, based on the unique molecular characteristics of each patient's tumor) has shown promise in improving outcomes for colon cancer patients. Omics sciences and precision medicine hold great promise for identifying new therapeutic targets and developing more effective treatments for colon cancer. Although not strictly designed as a systematic review, this review provides a readily accessible and up-to-date summary of the latest developments in the field, highlighting the challenges and opportunities for future research.

查看原文本刊更多论文

结肠癌的组学科学和精准医学。

摘要:结肠癌具有复杂的病理生理环境，这对患者预后和治疗反应的准确预测提出了重大挑战。然而，基因组学、转录组学、蛋白质组学和代谢组学等组学科学的出现，为识别参与结肠癌发生和进展的分子改变和途径提供了强有力的工具。为了解决缺乏探索组学科学、精准医学和结肠癌交叉领域的文献，我们在ScienceDirect和PubMed数据库中进行了全面的搜索。我们纳入了2015-2023年间发表的系统综述、综述、病例研究、临床研究和随机对照试验。为了完善我们的搜索，我们排除了摘要和非英语研究。本文综述了目前对精确医学和组学科学在结肠癌研究中的最新进展的理解。研究已经根据基因组和转录组学谱确定了结肠癌的分子亚型，这对预后和治疗选择具有重要意义。此外，精准医学(根据每位患者肿瘤的独特分子特征进行量身定制的治疗)在改善结肠癌患者的预后方面显示出了希望。组学科学和精准医学为确定新的治疗靶点和开发更有效的结肠癌治疗方法带来了巨大的希望。虽然没有严格设计为系统综述，但本综述提供了该领域最新发展的易于获取的最新摘要，突出了未来研究的挑战和机遇。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Terapeutica PHARMACOLOGY & PHARMACY-

CiteScore

2.50

自引率

0.00%

发文量

124

审稿时长

6-12 weeks

期刊介绍： La Clinica Terapeutica è una rivista di Clinica e Terapia in Medicina e Chirurgia, fondata nel 1951 dal Prof. Mariano Messini (1901-1980), Direttore dell''Istituto di Idrologia Medica dell''Università di Roma “La Sapienza”. La rivista è pubblicata come “periodico bimestrale” dalla Società Editrice Universo, casa editrice fondata nel 1945 dal Comm. Luigi Pellino. La Clinica Terapeutica è indicizzata su MEDLINE, INDEX MEDICUS, EMBASE/Excerpta Medica.